CN Patent

CN114042041A — 局部药物组合物

Assigned to Demavan Science Co ltd · Expires 2022-02-15 · 4y expired

What this patent protects

本发明涉及局部药物乳液组合物，其包含治疗有效量的3,5‑二羟基‑4‑异丙基‑反式‑均二苯乙烯或其药学上可接受的盐、油相、水相、表面活性剂和抗氧化剂，其中所述乳液组合物是均质的和/或所述活性物质溶于油相中。本发明还涉及通过将本发明的组合物施用于患者皮肤来治疗患者的皮肤病症或障碍的方法。

USPTO Abstract

本发明涉及局部药物乳液组合物，其包含治疗有效量的3,5‑二羟基‑4‑异丙基‑反式‑均二苯乙烯或其药学上可接受的盐、油相、水相、表面活性剂和抗氧化剂，其中所述乳液组合物是均质的和/或所述活性物质溶于油相中。本发明还涉及通过将本发明的组合物施用于患者皮肤来治疗患者的皮肤病症或障碍的方法。

Drugs covered by this patent

Patent Metadata

Patent number
CN114042041A
Jurisdiction
CN
Classification
—
Expires
2022-02-15
Drug substance claim
No
Drug product claim
No
Assignee
Demavan Science Co ltd
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.